SCHEMBL2942935

SCHEMBL2942935

COc1ccc2cc(-c3cnc(Cc4ccccc4)o3)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 8/20 0.49
CYP11B2 P19099 8/20 0.49
CYP17A1 P05093 2/20 0.48
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
GPR55 Q9Y2T6 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
FAAH O00519 2/20 0.45
CLK1 P49759 1/20 0.44
DYRK1A Q13627 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950785 0.90 CYP1A2 (0.46) CYP11B1CYP11B2CYP17A1LMNAMAPT
SCHEMBL2942318 0.83 PTPN7 (0.53) LMNARAB9ANPC1SMN1; SMN2
SCHEMBL4871514 0.82 RAB9A (0.62) LMNAMAPTTSHRMAPK1HTT
SCHEMBL2951660 0.82 NOTUM (0.43) CYP11B1CYP11B2TSHRMAPK1RAB9A
SCHEMBL2943242 0.82 ESR2 (0.47) CYP11B1CYP11B2CYP17A1MAPK1FAAH
SCHEMBL2943848 0.81 PPARG (0.46)
SCHEMBL2949331 0.80 TSHR (0.59) CYP11B1CYP11B2CYP17A1LMNAMAPT
SCHEMBL2950936 0.79 PPARG (0.59)
SCHEMBL2946398 0.78 FFAR1 (0.39) LMNAMAPTTSHRMAPK1HTT
SCHEMBL2943816 0.76 PTPN7 (0.56) LMNAMAPTMAPK1HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754747-B2 Oxazolo-naphthyl acids WYETH LLC (US) 2010-07-13 US disclosed
EP-1781645-A1 OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES Wyeth (US) 2007-05-09 EP disclosed
US-20060052348-A1 Oxazolo-naphthyl acids WYETH (US) 2006-03-09 US disclosed
WO-2006023865-A1 OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES WYETH (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052348-A1 Oxazolo-naphthyl acids SERPINE1, SERPINB1, SERPINC1 CYP11B1 82/4885CYP11B2 88/4885CYP17A1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.